David C Klonoff
David C Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE is an expert in Endocrinology at Mills Peninsula Health Services (United States). As of November 2026, ScienceLeadR ranks David C Klonoff in the top 1% of experts worldwide for Diabetes Mellitus, Glucose Metabolism Disorders and Continuous Glucose Monitoring. David C Klonoff has authored 478 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 1 of them ongoing. SLR score: 2,086 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Public Health - Gastroenterology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology. He is Chair of the Endocrinology Research Advisory Committee at Sutter Health Research Institute, and a Clinical Professor of Medicine at UCSF. Dr. Klonoff received the American Diabetes Association’s 2019 Outstanding Physician Clinician Award. He received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. He received the IEEE Standards Association Conformity Assessment Award in 2022. In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology.He was named an Avant-garde All-Star in 2025 for being in the top 1% of US endocrinology researchers. He was ranked by ScienceLeadR in 2026 as being among the top 1% of experts worldwide in diabetes, continuous glucose monitoring, computer security, computing methodologies, and glucose metabolism disorders. He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India. Dr. Klonoff was invited to speak to the US Congressional Diabetes Caucus in 2017, participate in the White House Health and Cybersecurity Roundtable in 2015, and speak at the European Parliament in 2010. Dr. Klonoff is a graduate of UC Berkeley, (Phi Beta Kappa, Junior Year) and UCSF Medical School (Alpha Omega Alpha, Junior Year.) His postgraduate training included two years at UCLA Hospital and three years at UCSF Hospitals.
Organizations
University of California, San Francisco
2025 - 2025
Number : 478
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial. PMID 42747817 — glucagon-like peptide 1, quality of life, safety, cardiovascular diseases, frailty, semaglutide | JAMA Cardiol | 2026 | 2 |
| Image-Based Dietary Assessment Using Multimodal Large Language Models: Performance, Limitations, and Clinical Applicability in Diabetes. PMID 42996283 — diabetes mellitus, nutrients, language, diet, food, meals, carbohydrates, diet, healthy | medRxiv | 2026 | 0 |
| DiaBench: A Benchmarking Framework to Evaluate the Performance of LLMs in T2D Patient Education. PMID 42990471 — diabetes mellitus, education, patient education as topic, benchmarking | medRxiv | 2026 | 0 |
| One Size Does Not Fit All: The Need for Sex-Specific Precision Medicine in Diabetes Technology. PMID 40413613 — diabetes mellitus, exercise, menstrual cycle, insulin, puberty, aging, reproductive health, sex, precision medicine, research, menopause, gonadal steroid hormones | J Diabetes Sci Technol | 2025 | 2 |
| Insulin pens and the digital ecosystem. PMID 42776165 — diabetes mellitus, insulin, ecosystem, therapeutics | Diabetologia | 2026 | 1 |
Clinical Studies 20
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Continuous Glucose Monitoring in Intensive Care Unit NCT05585801 — diabetes mellitus, research design, blood glucose, insulin, blood, biochemistry, point-of-care systems, insemination, artificial, heterologous, critical care, therapeutics, intensive care units, continuous glucose monitoring | N/A | Active not recruiting | 2022 |
LeadR Networks
Main global connection map